Who makes Cisplatin, Gemcitabine, Panitumumab?

Cisplatin, Gemcitabine, Panitumumab is developed by Hannover Medical School.

What development phase is Cisplatin, Gemcitabine, Panitumumab in?

Cisplatin, Gemcitabine, Panitumumab is in Phase 2.

Last reviewed 2026-04-19 · How we verify

Cisplatin, Gemcitabine, Panitumumab

Hannover Medical School · Phase 2 active Small molecule

At a glance

Generic name	Cisplatin, Gemcitabine, Panitumumab
Also known as	Vectibix (Panitumumab), Gemzar (Gemcitabine), Cisplatin 0.5mg/ml solution medac (Cisplatin)
Sponsor	Hannover Medical School
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

PiCCA Study (Panitumumab in Combination With Cisplatin/Gemcitabine) (PHASE2)
PURO Panitumumab in Combination With Gemcitabine/Cisplatin in Advanced Urothelial Cancer (PHASE2)
Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Patients With Advanced Cancer (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Cisplatin, Gemcitabine, Panitumumab CI brief — competitive landscape report
Cisplatin, Gemcitabine, Panitumumab updates RSS · CI watch RSS
Hannover Medical School portfolio CI